A Phase 1/2 Study of the Safety and Efficacy of Ulocuplumab Combined with Nivolumab in Subjects with Advanced or Metastatic Solid Tumors (CXCessoR4: Clinical trial of the anti-CXCR4 antibody ulocuplumab in malignant tumors)
A study for patients with advanced or metastatic solid tumors using study drug ulocuplumab combined with nivolumab
Sponsor: Bristol-Myers Squibb
Enrolling: Male and Female Patients
IRB Number: AAAP5904
Contact: Naiyer Rizvi: 646-317-6344 / nar2144@columbia.edu
Additional Study Information: This study is an open-label, multicenter phase 1/2 study. The study is designed in two parts, the first is designed to evaluate the safety of the study drug ulocuplumab in combination with nivolumab in subjects with small cell lung cancer (SCLC) and pancreatic adenocarcinoma (PAC). Subjects will receive a low dose of ulocuplumab in combination with nivolumab which will be increased to determine the maximum tolerated dose (MTD). This dose level will then be used in a dose expansion phase to further determine the safety profile of the study drugs. The second part will evaluate how well the study drug works on the body when given in combination with nivolumab.
This study is closed
Do You Qualify?
Do you have a confirmed diagnosis of pancreatic adenocarcinoma (PAC) or small cell lung cancer (SCLC)? Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Naiyer Rizvi